Comparison of sirolimus‐eluting stent and paclitaxel‐eluting stent for long‐term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry

Abstract

The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM.

Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus

“…They showed no significant differences between SES and PES with regard to death/MI (PES 14.7% vs. SES 18.2%), target vessel revascularization (TVR) (PES 9.7% vs. SES 15.3%), and stent thrombosis (PES 2.4% vs. SES 4.4%) (14). In addition, the KOMATE registry, comparing 3-year outcomes in 634 diabetic patients, found no important difference in MACE or stent thrombosis between PES and SES (15). …”

“…Very few studies have compared the risk of very late stent thrombosis between SES and PES in this high-risk patient population. The KOMATE registry showed no significant difference in stent thrombosis between SES and PES in patients with diabetes at 3 years (2.8% in SES vs. 3.5% in PES) (15). In ARTS-II, the rate of definite or probable stent thrombosis in diabetic patients receiving a SES at 3 years was 5.0% (25).…”

Comparison of 2‐year clinical outcomes with sirolimus and paclitaxel‐eluting stents for patients with diabetes: Results of the Registro Regionale AngiopLastiche Emilia‐Romagna Registry

“…Several registry and randomized controlled studies comparing the use of SES and PES for patients with diabetes have been published [6‐11, 14, 15]. This is the largest published report with a 2‐year follow‐up in a real‐world setting.…”

“…Randomized clinical trials report a superiority of SES in terms of reduced in‐stent and in‐segment late loss, and TVR at a 9‐month follow‐up, while death, myocardial infarction and MACE incidence are equivalent [6‐9]. Registry studies, with relatively longer clinical follow up, demonstrate similar results for SES and PES in patients with diabetes [10, 12, 15, 16]. Recent metanalyses of randomized clinical trials (Stettler) and of both RCT's and registries (Mahmud) demonstrate that stent type do not influence clinical outcome in patients with diabetes [18, 19].…”

“…Head‐to‐head comparisons between sirolimus eluting stents and paclitaxel eluting stents in patients with DM have shown SES to be superior in terms of angiographic late loss but not of clinical endpoints [6‐9]. Moreover, while confirming the beneficial effect of SES and PES in patients with DM, registry studies [10‐15] do not report significant differences in outcome and underscore the still high prevalence of major cardiac adverse events (MACE) and stent thrombosis (ST) in this population. The purpose of this retrospective study is to analyze the long‐term relative benefits of using different types of DES in a large cohort of diabetic patients submitted to PCI in a real‐world multicentre registry.…”